WHO ICTRP trial
Hemolysis, elevated liver functions and low platelets (HELLP syndrome): Does the…
ACTRN12610001007022 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12610001007022 |
|---|---|
| Public title | Hemolysis, elevated liver functions and low platelets (HELLP syndrome): Does the use of dexamethasone in the postpartum period improve maternal outcome? |
| Scientific title | Hemolysis, elevated liver functions and low platelets (HELLP syndrome): Does the use of dexamethasone in the postpartum period improve maternal hospital stay and complications? |
| Primary sponsor | Universitas Hospital |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 / Phase 4 |
| Countries | South Africa |
| Conditions | HELLP syndrome; HELLP syndrome;Reproductive Health and Childbirth - Fetal medicine and complications of pregnancy |
| Interventions | Patients with HELLP syndrome was randomised to receive either dexamethasone or no dexamethasone in postpartum peroid. the dose of dexamethasone was 24 mg on day 1, 16mg on day2 and 12 mg on day 3 and it was given intravenously. |
| Registration date | Nov 18, 2010 |
| Target size | 66 |
| Secondary IDs | nil |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: